Genentech reports Phase II data show enicepatide delivers clinically meaningful weight loss in overweight, obesity study

Genentech flagged new Phase II obesity data for enicepatide and petrelintide to be presented at the ADA 2026 Scientific Sessions.
The late-breaking readouts showed meaningful weight-loss benefits with safety profiles that support longer-term use, positioning both assets for broader development.
Petrelintide data also pointed to favorable tolerability, a potential differentiator in a crowded weight-management market.
The company is moving both programs into Phase III, aiming to strengthen its competitive stance in cardiometabolic medicines.
A Phase II multi-arm trial of fixed-dose combinations of enicepatide and petrelintide is scheduled to start around mid-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genentech Inc. published the original content used to generate this news brief on May 31, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.